Evidence & regulatory context
- Mechanism
- Human bone-marrow MSCs; recombinant CCL5 in a separate arm; cell/protein therapy.
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseSpinal cord injuryComplete transectionC57BL/6 wild typeMalen = 139 animals in total; hMSC n = 40, HBSS n = 26, no-injectio…Intraparenchymal spinal cord injection between T10 and T11, 29G needle, 0.5 microlitres per minute5 x 10^5 hMSCs in 0.5 microlitres of HBSS; recombinant mous…hMSCs on postoperative day 1 (24 hours after injury); recombinant CCL5 on posto…
Model: Complete spinal cord transection between T9 and T10 with a thin-bladed razor under sevoflurane anaesthesia
hMSC transplantation improved locomotor score from day 3 to day 14, raised Ccl2 about 16-fold at day 3 and Ccl5 about 11-fold at day 14, suppressed Aif1, Elane and Mpo at day 3, and increased the alternatively activated macrophage markers Arg1 and Chil3 and the axonal regeneration markers Dpysl2 an…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.